Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away.
It's not supposed to work that way. The further you get down the pipeline, the better your shot at success. By the end of Phase 2, investigators are supposed to have a solid set of significant safety and efficacy data on humans. Phase 3 is where the big bets are made, based on good science and some unprecedented demands for new products. . .View Full Article